Enveric Biosciences (ENVB) Other Working Capital Changes (2011 - 2026)
Enveric Biosciences (ENVB) posted Other Working Capital Changes of $29453.0 for Q4 2025.
Enveric Biosciences (ENVB) Other Working Capital Changes (2011 - 2026) Analysis & Trends
Enveric Biosciences has reported Other Working Capital Changes for 14 years, with the latest figure at $251611.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 445.49% year-over-year to $251611.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45453.0 (up 94.9% YoY) and the FY2025 annual result came in at -$250938.0, down 40.58% from the prior year.
- Other Working Capital Changes steadied at $29453.0 in Q4 2025 per ENVB's latest filing.
- Over five years, Other Working Capital Changes peaked at $1.5 million in Q1 2023 and troughed at -$739176.0 in Q4 2023.
- A 5-year average of $11946.6 and a median of -$118143.0 in 2025 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes soared 789.58% in 2022, then sank 198.74% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$384361.0 in 2022, then plunged by 92.31% to -$739176.0 in 2023, then jumped by 75.35% to -$182170.0 in 2024, then soared by 35.15% to -$118143.0 in 2025, then soared by 312.97% to $251611.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $251611.0, -$118143.0, and -$84603.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251,611.00 |
| Mar 31, 2026 | 251,611.00 |
| Mar 31, 2026 | 251,611.00 |
| Dec 31, 2025 | -118,143.00 |
| Dec 31, 2025 | -118,143.00 |
| Dec 31, 2025 | -118,143.00 |
| Sep 30, 2025 | -84,603.00 |
| Sep 30, 2025 | -84,603.00 |
| Sep 30, 2025 | -84,603.00 |
| Jun 30, 2025 | -94,318.00 |
| Jun 30, 2025 | -94,318.00 |
| Jun 30, 2025 | -94,318.00 |
| Mar 31, 2025 | 46,126.00 |
| Mar 31, 2025 | 46,126.00 |
| Mar 31, 2025 | 46,126.00 |
| Dec 31, 2024 | -182,170.00 |
| Dec 31, 2024 | -182,170.00 |
| Dec 31, 2024 | -182,170.00 |
| Sep 30, 2024 | -540,148.00 |
| Sep 30, 2024 | -540,148.00 |